Inclusion Criteria:  18 to 45 years old, male or female; Weight: Male subjects should not be less than 50.0kg and female subjects should not be less than 45.0kg, BMI within the range of 19.0 and 26.0 kg/m2(Including the threshold); Eyes corrected visual acuity should be ≥ 1.0 in both eyes and intraocular pressure, slit lamp and fundus examination were normal or abnormality with no clinical significance; The female subjects should be guaranteed to take effective contraception before selected in within a month prior，and all the subjects Regardless of the gender are willing to take effective contraception and no pregnancy is planned for the next 6 months; Volunteer to participate in the study and sign informed consent.  Exclusion Criteria:  With ocular diseases, including a history of inner eye surgery or laser surgery; Subjects who had worn contact lenses within 2 weeks prior screening or need to wear it during the study; Subjects who had taken any medicine including Eye ophthalmic drug within 2 weeks prior screening； Subjects with a history of central nervous, mental, cardiovascular, renal, liver, respiratory, metabolic and musculoskeletal systems; Subjects'pretest physical examination, vital signs, ELECTRO cardiogram, laboratory examination and investigator's determination of abnormality with clinical significance. The results of eight immunological tests(HBsAg、HBsAb、HBEAG、HABEAB、HbcAb、HCVAb、TPPA、HIV-P24 Antigen/antibody) is abnormality with clinical significance. A history of clinically significant allergy, especially drug allergy, allergy to aspirin or other non-steroidal anti-inflammatory drugs or known allergy to the drug component or biphenylacetic acid; The average daily smoking amount in the first 3 months was more than 5 cigarettes; Alcohol dependence is suspected or confirmed, with alcohol intake averaging more than 2 units per day for 3 months (1 unit =10 mL ethanol, i.e. 1 unit =200 mL beer at 5% alcohol or 25 mL spirits at 40% alcohol or 83 mL wines at 12% alcohol) or alcohol tests positive; A history of drug abuse, or positive urine tests for ketamine, morphine, methylamphetamine, dimethylene dioxymethamphetamine, or tetrahydrocannabinic acid; Participation in other the clinical trial within 3 months before; Blood donation or blood loss ≥400 mL within 3 months before; Pregnant or lactating women and those planning to become pregnant; Subjects with a history of needle and blood dizziness or intolerance to venipuncture; The investigator thinks it is not suitable to participate in this study.